Case Study

Improving Enrollment For Challenging Protocol

iStock-1292777578-autoinjector-injector-device-patient

A biopharma company developed an ingestible powder composed of non-digestible oligosaccharides specifically for patients with ulcerative colitis (UC), with a goal of positively affecting their gut microbiomes. The study needed to enroll 30 subjects with mild to moderate UC symptoms both domestically and abroad. Elligo was brought on to assist with enrolling 20 subjects in the U.S. 

Find out the challenges and solutions in the available case study.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Hydrocarbon Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: